We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENVX:NASDAQEnovix Corporation Analysis

Data as of 2026-03-31 - not real-time

$5.11

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Technical snapshot: ENVX is trading at $5.11, just above its 20‑day SMA ($5.03) but well below the 50‑day ($5.85) and 200‑day ($9.13) averages, signaling a short‑term bounce within a broader bearish framework. The RSI sits at 45.8 (neutral), while the MACD histogram is positive and the signal line is flagged bullish, hinting at limited upside momentum toward the nearby resistance of $5.55. However, volatility is extreme at 67.7% over 30 days and beta exceeds 2.5, underscoring a highly volatile, market‑sensitive stock.
Fundamental & news backdrop: The company posted a 38% revenue jump to $31.8 M in 2025, with Q4 record shipments to defense and industrial customers, fueling analyst optimism around its next‑generation lithium‑ion technology. Yet margins remain deep in the red (operating margin –3.9%), cash flow is negative, and debt ($544 M) dwarfs cash ($512 M), yielding a debt‑to‑equity ratio near 200. With a forward P/E of –10.1, price‑to‑book at 3.97, and price‑to‑sales over 34×, the stock appears materially overvalued relative to its earnings and balance‑sheet health.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above the $4.61 support level
  • Bearish longer‑term moving averages (50‑day & 200‑day SMAs)
  • High 30‑day volatility and beta >2.5

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • 38% YoY revenue growth driven by defense and industrial battery shipments
  • Positive MACD histogram indicating emerging momentum
  • Analyst enthusiasm for high‑energy‑density battery technology

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic positioning in EV, wearables, and defense markets
  • Substantial cash cushion despite high debt levels
  • Upside target potential (~$14) far exceeding current price

Key Metrics & Analysis

Financial Health

Revenue Growth15.90%
P/E Ratio-10.1
ROE-59.84%
ROA-15.70%
Debt/Equity198.64
P/B Ratio4.0
Op. Cash Flow$-95291000
Free Cash Flow$-58625376
Industry P/E28.5

Technical Analysis

TrendBearish
RSI45.8
Support$4.61
Resistance$5.55
MA 20$5.03
MA 50$5.85
MA 200$9.13
MACDBullish
VolumeStable
Fear & Greed Index74.52

Valuation

Target Price$14.45
Upside/Downside183.06%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.50
Volatility67.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.